tbuckley/cabot-search huggingface dataset:
Preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer: Results of a phase II study and the role of apparent diffusion coefficient (ADC) by diffusion-weighted magnetic resonance imaging (DW MRI) for prediction of pathologic responses.
Authors: E. M. Lee, J. L. Hong, J. L. Lee, S. Y. Kim, Y. S. Park, J. H. Kim, C. S. Yu, J. C. Kim, A. Y. Kim, T. W. Kim
Journal: Journal of Clinical Oncology (2011)

629 Background: We conducted a phase II study of preoperative chemoradiation (CRT) with S-1, a novel oral fluoropyrimidine, plus oxaliplatin in patients (pts) with locally advanced rectal cancer. Tumor ADCs were measured by DW-MRI and were evaluated as a predictive marker for pathologic responses. Methods: Radiotherapy was delivered to a total 50.4 Gy. The recommended doses were determined by a previous phase I study; oxaliplatin 50 mg/m 2 /week on D1, 8, 22 and 29, and S-1 80 mg/m 2 /day on D1-14 and D22-35. Total mesorectal excision was performed within 6 ± 2 weeks. Primary endpoint was pathologic complete response (pCR) rate. The value of tumor ADCs by DW-MRI was measured before and after CRT, and was correlated with pathologic responses after surgery. Results: A total of 38 patients were enrolled; 22 (57.9%) were men and the median age was 54 years (range, 28-67). Of 35 patients who underwent curative surgery, 28 patients underwent sphincter-saving operations. There was no grade 4 toxicity, and grade 3 toxicities included leukopenia (2.7%), neutropenia (2.7%), anorexia (2.7%), nausea (2.7%) and diarrhea (8.8%). The pCR rate was 25.7% (8/35, 95% CI [10.9-42.1]) and additional 10 patients (28.6%) showed near total regressions of tumor. Tumor ADCs by DW-MRI were calculated in 38 patients (including phase I part). The post-CRT ADC and the ADC changes (ΔADC) were significantly correlated with pCR rate (post-CRT ADC: 1.52±0.46 vs. 1.07±0.58, p=0.037, ΔADC: 44.5% vs. -7.6%, p=0.026). Conclusions: Preoperative CRT with S-1 plus oxaliplatin showed promising results in pathologic responses and favorable toxicities profiles. Tumor ADC by DW-MRI seems to be a useful method for predicting responses. No significant financial relationships to disclose.
Velcade, Vorinostat and Dexamethasone (V2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial
Authors: Matthew W Jenner, Avie-Lee Tillotson, Sarah R Brown, Louise M Flanagan, Debbie Sherratt, Charlotte Pawlyn, Cathy Williams, Faith E Davies
Journal: Blood (2015)
Clonality Analysis as a Tool To Study the Immunologic Reconstitution with Leukemia Patients Following Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Xin Du, Yangqiu Li, Jianyu Weng, Zesheng Lu, Rong Xie, Shaohua Chen, Lijian Yang, Wei Lin, Zhilun Huang
Journal: Blood (2004)
Gut microbial degradation of organophosphate insecticides-induces glucose intolerance via gluconeogenesis
Authors: Ganesan Velmurugan, Tharmarajan Ramprasath, Krishnan Swaminathan, Gilles Mithieux, Jeyaprakash Rajendhran, Mani Dhivakar, Ayothi Parthasarathy, D.D. Venkatesh Babu, Leishman John Thumburaj, Allen J. Freddy, Vasudevan Dinakaran, Shanavas Syed Mohamed Puhari, Balakrishnan Rekha, Yacob Jenifer Christy, Sivakumar Anusha, Ganesan Divya, Kannan Suganya, Boominathan Meganathan, Narayanan Kalyanaraman, Varadaraj Vasudevan, Raju Kamaraj, Maruthan Karthik, Balakrishnan Jeyakumar, Albert Abhishek, Eldho Paul, Muthuirulan Pushpanathan, Rajamani Koushick Rajmohan, Kumaravel Velayutham, Alexander R. Lyon, Subbiah Ramasamy
Journal: Genome biology (2017)

Organophosphates are the most frequently and largely applied insecticide in the world due to their biodegradable nature. Gut microbes were shown to degrade organophosphates and cause intestinal dysfunction. The diabetogenic nature of organophosphates was recently reported but the underlying molecular mechanism is unclear. We aimed to understand the role of gut microbiota in organophosphate-induced hyperglycemia and to unravel the molecular mechanism behind this process. Here we demonstrate a high prevalence of diabetes among people directly exposed to organophosphates in rural India (n = 3080). Correlation and linear regression analysis reveal a strong association between plasma organophosphate residues and HbA1c but no association with acetylcholine esterase was noticed. Chronic treatment of mice with organophosphate for 180 days confirms the induction of glucose intolerance with no significant change in acetylcholine esterase. Further fecal transplantation and culture transplantation experiments confirm the involvement of gut microbiota in organophosphate-induced glucose intolerance. Intestinal metatranscriptomic and host metabolomic analyses reveal that gut microbial organophosphate degradation produces short chain fatty acids like acetic acid, which induces gluconeogenesis and thereby accounts for glucose intolerance. Plasma organophosphate residues are positively correlated with fecal esterase activity and acetate level of human diabetes. Collectively, our results implicate gluconeogenesis as the key mechanism behind organophosphate-induced hyperglycemia, mediated by the organophosphate-degrading potential of gut microbiota. This study reveals the gut microbiome-mediated diabetogenic nature of organophosphates and hence that the usage of these insecticides should be reconsidered.
Abstract 16003: Rapid Whole Genome Sequencing for Critically Ill Children With Cardiomyopathy
Authors: Paul A van der Zwaag, Johanna C Herkert, Gideon J du Marchie Sarvaas, Beatrijs Bartelds, Cleo C van Diemen, Tom J de Koning, Jan D Jongbloed, Birgit Sikkema-Raddatz, Lude Franke, Richard J Sinke, Irene M van Langen, Cisca Wijmenga, Wilhelmina S Kerstjens-Frederikse
Journal: Circulation (2016)

Introduction: Rapid whole genome sequencing (WGS) has been explored as a novel diagnostic tool in severely ill newborns, in order to replace time consuming genetic tests. Retrospective studies show...
Stroma-Free Ex Vivo Expanded, CD34+ Cord Blood-Derived NK Cells Retain Lytic Activity After Long-Term Engraftment in NSGS Mice
Authors: Mark Wunderlich, Mahesh Shrestha, Lin Kang, Eric Law, Vladimir Jankovic, Xiaokui Zhang, Uri Herzberg, Stewart Abbot, Robert Hariri, James C. Mulloy
Journal: Blood (2012)
Identification of Novel Biomarkers for Prediction of Response to Tyrosine Kinase Inhibitors (TKIs) by Proteomic Profiling of Imatinib as Well as 2nd and 3rd Generation TKIs in Vitro
Authors: Stefan Balabanov, Thoma Wilhelm, Simone Venz, Christine Barret, Gunhild Keller, Mirja Bernhardt, Artur Gontarewicz, Melanie Braig, Reinhard Walther, Tim H. Brummendorf
Journal: Blood (2008)
Association Between The Real Cost Media Campaign and Smoking Initiation Among Youths — United States, 2014–2016
Authors: Matthew C. Farrelly, Jennifer C. Duke, James Nonnemaker, Anna J. MacMonegle, Tesfa N. Alexander, Xiaoquan Zhao, Janine C. Delahanty, Pamela Rao, Jane A. Allen
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

In the United States, approximately 900,000 youths smoke their first cigarette each year (1). Health communication interventions are evidence-based strategies for preventing the initiation of tobacco use, promoting and facilitating cessation, and changing beliefs and attitudes about tobacco use (2,3). This report describes the association between the Food and Drug Administration's (FDA's) first national tobacco public education campaign, The Real Cost, and rates of smoking initiation among youths in the United States from 2014 to 2016. A nationally representative cohort study of youths (N = 5,185) was conducted during November 2013-March 2016. Results from a discrete-time survival model indicate that, among youths who reported never having smoked a cigarette in the baseline survey, the odds of reporting smoking initiation at follow-up were lower among youths with frequent exposure to campaign advertisements than among those with little or no exposure (adjusted odds ratio [aOR] = 0.70, 95% confidence interval [CI] = 0.55-0.91). Based on the results of the model, The Real Cost is associated with an estimated 348,398 U.S. youths aged 11-18 years who did not initiate smoking during February 2014-March 2016. Sustained youth-focused tobacco education campaigns, such as The Real Cost, can help speed progress toward preventing tobacco use among youths in the United States.
Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.
Authors: Ranjani Ramamurthy, Todd A. Alonzo, Robert B. Gerbing, Michael R. Loken, Laura Pardo, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Samir Kahwash, Amy Heerema-McKenney, Laura Winter, Kathleen Glick, Patti Byron, Laura E Francisco, Robert S Lavey, Stella M. Davies, Franklin O. Smith, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2012)
Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Authors: Ruth J. Pepper, Juliana B. Draibe, Ben Caplin, Fernando C. Fervenza, Gary S. Hoffman, Cees G. M. Kallenberg, Carol A. Langford, Paul A. Monach, Philip Seo, Robert Spiera, E. William St.Clair, Nadia K. Tchao, John H. Stone, Ulrich Specks, Peter A. Merkel, Alan D. Salama
Journal: Arthritis & Rheumatology (2016)

S100A8/A9 (calprotectin) has shown promise as a biomarker for predicting relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This study was undertaken to investigate serum S100A8/A9 level as a biomarker for predicting future relapse in a large cohort of patients with severe AAV.Serum levels of S100A8/A9 were measured at baseline and months 1, 2, and 6 following treatment initiation in 144 patients in the Rituximab in ANCA-Associated Vasculitis trial (cyclophosphamide/azathioprine versus rituximab [RTX] for induction of remission) in whom complete remission was attained.Patients were divided into 4 groups: proteinase 3 (PR3)-ANCA with relapse (n = 37), PR3-ANCA without relapse (n = 56), myeloperoxidase (MPO)-ANCA with relapse (n = 6), and MPO-ANCA without relapse (n = 45). Serum S100A8/A9 level decreased in all groups during the first 6 months of treatment. The percentage reduction from baseline to month 2 was significantly different between patients who experienced a relapse and those who did not in the PR3-ANCA group (P = 0.046). A significantly higher risk of relapse was associated with an increase in S100A8/A9 level between baseline and month 2 (P = 0.0043) and baseline and month 6 (P = 0.0029). Subgroup analysis demonstrated that patients treated with RTX who had increased levels of S100A8/A9 were at greatest risk of future relapse (P = 0.028).An increase in serum S100A8/A9 level by month 2 or 6 compared to baseline identifies a subgroup of PR3-ANCA patients treated with RTX who are at higher risk of relapse by 18 months. Since RTX is increasingly used for remission induction in PR3-ANCA-positive patients experiencing a relapse, S100A8/A9 level may assist in identifying those patients requiring more intensive or prolonged treatment.
Warfarin-Associated Nonuremic Calciphylaxis
Authors: Wesley Yung-Hsu Yu, Tina Bhutani, Rachel Kornik, Laura B. Pincus, Theodora Mauro, Michael D. Rosenblum, Lindy P. Fox
Journal: JAMA Dermatology (2017)

<h3>Importance</h3> Classic calciphylaxis associated with renal failure is a life-threatening disease. Warfarin-associated calciphylaxis without renal injury has been described, but whether it is a subset of classic calciphylaxis or a different entity remains unknown. We describe 1 case of warfarin-associated calciphylaxis, present data from 2 others from our institution, and review all cases of warfarin-associated calciphylaxis available in the literature. Our review indicates that warfarin-associated calciphylaxis is clinically and pathophysiologically distinct from classic calciphylaxis. <h3>Objective</h3> To review warfarin-associated calciphylaxis and determine its relationship to classic calciphylaxis. <h3>Design, Setting, and Participants</h3> We searched MEDLINE and Ovid without language or date restrictions for case reports of calciphylaxis from the inpatient setting using the terms "calciphylaxis and warfarin," "non-uremic calciphylaxis," and "nonuremic calciphylaxis." We defined nonuremic calciphylaxis as a histopathologic diagnosis of calciphylaxis without severe kidney disease (serum creatinine level &gt;3 mg/dL; glomerular filtration rate &lt;15 mL/min; acute kidney injury requiring dialysis; and renal transplantation). <h3>Exposures</h3> Each patient had been exposed to warfarin before the onset of calciphylaxis. <h3>Main Outcomes and Measures</h3> Patient data were abstracted from published reports. Original patient medical records were requested and reviewed when possible. <h3>Results</h3> We identified 18 patients with nonuremic calciphylaxis, 15 from the literature, and 3 from our institution. Patients were predominantly female (15 of 18 [83%]) with ages ranging from 19 to 86 years. Duration of warfarin therapy prior to calciphylaxis onset averaged 32 months. Lesions were usually located below the knees (in 12 of 18 [67%]). No cases reported elevated calcium-phosphate products (0 of 17 [0%]). Calcifications were most often noted in the tunica media (n = 8 [44%]) or in the vessel lumen and tunica intima (n = 7 [39%]). The most common treatments included substitution of heparin or low-molecular weight heparin for warfarin (n = 13 [72%]), intravenous sodium thiosulfate (n = 9 [50%]), and hyperbaric oxygen (n = 3 [17%]). The survival rate on hospital discharge was remarkably high, with 15 cases (83%) reporting full recovery and 3 cases ending in death. <h3>Conclusions and Relevance</h3> Warfarin-associated calciphylaxis is distinct from classic calciphylaxis in pathogenesis, course, and, particularly, outcome. This finding should influence clinical management of the disease and informs targeted treatment of the disease.
Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party
Authors: Irit Avivi, Ariane Boumendil, Hervé Hervé Finel, Arnon Nagler, Aïda Sousa Bothello, Josep Maria Ribera Santasusana, Elisabeth A. Vandenberghe, Boris Afanasyev, Dominique Bordessoule, José Maria Moraleda, Eulogio Conde, David Pohlreich, Peter Dreger
Journal: Blood (2014)
Targeting and Regulating of an Oncogene via Nanovector Delivery of MicroRNA using Patient-Derived Xenografts
Authors: Shuyang Sun, Yilong Wang, Rong Zhou, Zicheng Deng, Yong Han, Xiao Han, Wenjie Tao, Zi Yang, Chaoji Shi, Duo Hong, Jiang Li, Donglu Shi, Zhiyuan Zhang
Journal: Theranostics (2017)

In precision cancer nanomedicine, the key is to identify the oncogenes that are responsible for tumorigenesis, based on which these genetic drivers can be each specifically regulated by a nanovector-directed, oncogene-targeted microRNA (miRNA) for tumor suppression.Fibroblast Growth Factor Receptor 3 (FGFR3) is such an oncogene.The molecular tumor-subtype harboring FGFR3 genomic alteration has been identified via genomic sequencing and referred to as the FGFR3-driven tumors.This genomics-based tumor classification provides further rationale for the development of the FGFR3-targeted miRNA replacement therapy in treating patients with FGFR3 gene abnormity.However, successful miRNA therapy has been hampered by lacking of an efficient delivery vehicle.In this study, a nanovector is developed for microRNA-100 (miR-100) -mediated FGFR3 regulation.The nanovector is composed of the mesoporous magnetic clusters that are conjugated with ternary polymers for efficient miRNA in-vivo delivery.The miRNA-loading capacity of the nanovector is found to be high due to the polycation polymer functionalized mesoporous structure, showing excellent tumor cell transfection and pH-sensitive miRNA release.Delivery of miR-100 to cancer cells effectively down-regulates the expression of FGFR3, inhibits cell proliferation, and induces cell apoptosis in vitro.Patient-derived xenografts (PDXs) are used to evaluate the efficacy of miRNA delivery in the FGFR3-driven tumors.Notably, sharp contrasts are observed between the FGFR3-driven tumors and those without FGFR3 genomic alteration.Only the FGFR3-driven PDXs are significantly inhibited via miR-100 delivery while the non-FGFR3-driven PDXs are not affected, showing promise of precision cancer nanomedicine.
Duration and Pathologic Correlates of Lewy Body Disease
Authors: Jonathan Graff-Radford, Jeremiah Aakre, Rodolfo Savica, Bradley Boeve, Walter K. Kremers, Tanis J. Ferman, David T. Jones, Kejal Kantarci, David S. Knopman, Dennis W. Dickson, Walter A. Kukull, Ronald C. Petersen
Journal: JAMA Neurology (2017)

Although patients with dementia with Lewy bodies (DLB) have shorter disease duration than patients with Alzheimer disease dementia, little is known about which factors influence disease duration among patients with DLB.To identify pathologic correlates of disease duration in participants with Lewy body disease (LBD).This observational study, performed from September 1, 2005, to June 1, 2015, using the National Alzheimer's Coordinating Center database included 807 participants with transitional or diffuse LBD.The study used Braak neurofibrillary tangle (NFT) stage, frequency of neuritic plaques, and LBD stage to determine whether pathologic variables are associated with disease duration.This study included 807 participants with transitional or diffuse LBD (mean [SD] age, 70.0 [9.9] at the onset of cognitive decline and 79.2 [9.8] years at death; 509 male [63.1%]). Shorter disease duration from cognitive symptom onset to death was observed in men (β, -0.73; 95% CI, -1.33 to -0.14; P = .02) and in those with a later age at onset (β, -0.11; 95% CI, -0.14 to -0.08; P < .001). Diffuse (neocortical) LBD was associated with shorter disease duration compared with transitional LBD (β, -1.52; 95% CI, -2.11 to -0.93; P < .001). Braak NFT stage and the presence of neuritic plaques were not significantly associated with differences in disease duration.Diffuse LBD was associated with shorter disease duration compared with transitional LBD, and this effect is independent of Braak NFT stage or extent of neuritic plaque disease. Identifying antemortem biomarkers of LBD stage may provide important prognostic information to patients with DLB.
Expression of Human Amyloidogenic Immunoglobulin Light Chains in Mice Leads to Organ Toxicity.
Authors: Jennifer E. Ward, Daniel Brenner, Lei Cui, Ronglih Liao, Lawreen H. Connors, Pam Soo Hoo, Jeremy Eberhard, Thomas Christensen, Carl O’Hara, Martha Skinner, David C. Seldin
Journal: Blood (2005)
Climate Change and Global Food Systems: Potential Impacts on Food Security and Undernutrition
Authors: Samuel S. Myers, Matthew R. Smith, Sarah Guth, Christopher D. Golden, Bapu Vaitla, Nathaniel D. Mueller, Alan D. Dangour, Peter Huybers
Journal: Annual Review of Public Health (2017)

Great progress has been made in addressing global undernutrition over the past several decades, in part because of large increases in food production from agricultural expansion and intensification. Food systems, however, face continued increases in demand and growing environmental pressures. Most prominently, human-caused climate change will influence the quality and quantity of food we produce and our ability to distribute it equitably. Our capacity to ensure food security and nutritional adequacy in the face of rapidly changing biophysical conditions will be a major determinant of the next century's global burden of disease. In this article, we review the main pathways by which climate change may affect our food production systems-agriculture, fisheries, and livestock-as well as the socioeconomic forces that may influence equitable distribution.
Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,
Authors: Annika Dufour, Stefan K Bohlander, Evelyn Zellmeier, Gudrun Mellert, Karsten Spiekermann, Stephanie Schneider, Purvi Kakadia, Wolfgang Hiddemann, Jan Braess, Sim Truong, Nancy Patten, Lin Wu, Galina Salogub, Philippe Solal-Celigny, Anna Dmoszynska, Tadeusz Robak, Boris V Afanasiev, Marco Montillo, John Catalano, Christian H. Geisler, David Dornan, Ming Lin, Ru-Fang Yeh, Martin Weisser, Guillemette Duchateau-Nguyen, Giuseppe Palermo
Journal: Blood (2011)
HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML
Authors: Etienne Paubelle, Alice Marceau, Florence Zylbersztejn, Mickael Dussiot, Ivan Cruz Moura, Pascale Cornillet-Lefebvre, Jacques Delaunay, Alan K. Burnett, Sylvie Castaigne, Philippe Guardiola, Norbert Ifrah, Hervé Dombret, Claude Preudhomme, Robert K Hills, Olivier Hermine
Journal: Blood (2015)
Novel Vector Control Approaches: The Future for Prevention of Zika Virus Transmission?
Authors: Lorenz von Seidlein, Alexander S. Kekulé, Daniel Strickman
Journal: PLoS Medicine (2017)

In a Perspective accompanying Abad-Franch and colleagues, Lorenz von Seidlein, Alexander Kekulé, and Daniel Strickman discuss the importance of developing effective strategies to minimize mosquito-borne transmission of human diseases.
Proteasome Inhibition Sensitizes Leukemic Cells to Anthracyclin-Induced Apoptosis by Increasing the Expression of Bim and Bax Pro-Apoptotic Proteins.
Authors: Arnaud Pigneux, François X. Mahon, François Moreau-Gaudry, Marie L. Néré, Francis Lacombe, Josy Reiffers, Vincent Praloran, Francis Belloc
Journal: Blood (2005)
Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.
Authors: John Gerecitano, Carol S. Portlock, Paul A. Hamlin, Craig H Moskowitz, Ariela Noy, David J. Straus, Philip Schulman, Otilia Dumitrescu, Debra Sarasohn, Jennifer Pappanicholaou, Alexia Iassonos, Zhigang Zhang, Endri Horanlli, Celeste N Rojas, Andrew D. Zelenetz, Owen A O'Connor
Journal: Blood (2009)
Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results
Authors: Shaji K. Kumar, Ravi Vij, Jonathan L. Kaufman, Joseph R. Mikhael, Thierry Facon, Brigitte Pegourie, Lotfi Benboubker, Philippe Moreau, Martine Amiot, Stefanie Alzate, Lura Morris, Jeremy Ross, Martin Dunbar, Ming Zhu, Paulo Maciag, Suresh Agarwal, Joel Leverson, Sari Heitner Enschede, Rod A. Humerickhouse, Cyrille Touzeau
Journal: Blood (2015)
Experience of a Brazilian Institution with Treatment of Adult Acute Lymphoblastic Leukemia.
Authors: Edilson D. Pinheiro, Luiz F. Prachia, Elvira R.P. Velloso, Beatriz Beitler, Valeria Bucheri, Juliana Pereira, Pedro E. Dorlhiac-Laccer, Dalton A.F. Chamone
Journal: Blood (2006)
Molecular Remission Can Be Attained in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphomas after Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (ALLO-SCT).
Authors: Lucia Farina, Matteo Carrabba, Anna Dodero, Elena Rizzo, Elisabetta Zorzan, Fabio Ciceri, Anna Locasciulli, Attilio Olivieri, Alessandro Rambaldi, Corrado Tarella, Alessandra Santoro, Francesca Patriarca, Andrea Bacigalupo, Paolo Corradini
Journal: Blood (2004)